Cipla’s Q3FY23 performance was largely in line with our estimates. Revenue grew 6% YoY to Rs58.1bn (I-Sec: Rs.58.8bn) driven by a strong uptick in US revenue (US$195mn, +8.9% QoQ), which partially benefitted from continued traction in Revlimid and a strong seasonal quarter of its key products.